Precision Cardiovascular Therapeutics Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is precision cardiovascular therapeutics market size?

USD 827.1 million in 2026 and USD 2087.6 million by 2036 at a 9.7% CAGR.

Sales for precision cardiovascular therapeutics is projected to expand at 9.7% CAGR between 2026 and 2036, increasing valuation from USD 827.1 million in 2026 to USD 2087.6 million by 2036. Personalized molecular testing helps doctors identify patients carrying specific genetic risks for cardiovascular disease. High-risk individuals still struggling to manage their cholesterol levels. A July 2025 Novartis release estimated for 4 in 5 patients with atherosclerotic cardiovascular disease missed their guideline-recommended LDL-C targets. This critical gap highlights the urgent clinical need for ongoing and effective lipid-lowering therapies. Commercial success in this field relies on accurately identifying patients and proving changes in biomarkers directly leading to better cardiovascular health.

The United States and Germany clinical programs prioritize biomarker validation and documented patient outcomes. Medical services in Japan and South Korea emphasize population-specific data interpretation alongside specialist follow-up care. International healthcare networks apply distinct regional criteria on evaluating new cardiovascular treatments. In September 2025, Our Future Health reported stating it had gathered genetic information from 650,870 volunteers. Such an extensive dataset significantly expands the evidence base available for cardiovascular drug discovery and precise patient identification.

Summary of Precision Cardiovascular Therapeutics Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Molecular selection progresses as cardiologists connect a biological finding with a measurable treatment decision. Commercial adoption requires diagnostic access and clinical ownership across the full care pathway. Cardiology teams favor therapies aimed at identified genetic or molecular disease mechanisms, since patient selection influences treatment benefit. Lipid-management programs compare biomarker response with cardiovascular outcomes prior to adding long-duration treatment. Inherited cardiomyopathy services require molecular confirmation prior to disease-modifying therapy, reducing exposure among patients lacking the target condition. Hospital committees assess delayed safety evidence for permanent interventions and repeat-dose medicines under separate review standards. Specialist education improves case recognition and referral quality across participating cardiology networks.
Product and Segment View	Genomics-guided care is expected to lead, followed by marketed therapies and gene therapy. Selection review concentrates on molecular eligibility and evidence applicable to routine cardiology practice. Genomics-guided is projected to secure 44.0% share in 2026, reflecting direct use of variant evidence during treatment selection. Marketed is anticipated to hold 42.0% share in 2026, aided by approved indications and established prescribing instructions. Gene therapy is likely to account for 41.0% share in 2026, reflecting interest in durable correction of pathogenic cardiovascular pathways.
Geography and Growth Outlook	Country development differs according to genomic research depth and specialist capacity. Commercial entry also reflects reimbursement review and access to molecular testing. United States is forecast to scale at 12.0% CAGR between 2026 and 2036, guided by large research cohorts and early treatment access. Japan demand is projected to grow at 11.8% CAGR during the forecast period, influenced by hospital-based biobanks and specialist concentration. UK sales are predicted to rise 10.9% CAGR from 2026 to 2036, backed by national genomic services and linked health records.
Competitive View	Competition centers on molecular target quality and cardiovascular outcome evidence. Commercial progress favors companies combining approved therapies with disease-specific medical education. Novartis and Amgen compete across lipid-focused treatment programs, using established cardiology channels and long-term outcome evidence. Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals shape RNA-based treatment options for inherited cardiovascular disorders. BridgeBio Pharma and CRISPR Therapeutics address cardiomyopathy and gene-editing programs with distinct monitoring requirements.
Analyst Perspective	Precision cardiovascular therapeutics convert molecular findings into treatment choices for defined patient groups. Durable commercial value requires representative evidence and diagnostic coordination across participating services. Clinical leaders assess therapy utility using cardiovascular outcomes measured across complete treatment pathways. Hospital teams value clear eligibility criteria, since diagnostic uncertainty weakens routine adoption. Population-specific evidence improves confidence among specialists treating diverse genetic and clinical profiles. - Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights

Source: Future Market Insights analysis, 2026.

How is precision cardiovascular therapeutics market segmented?

The precision cardiovascular therapeutics sector is segmented by therapy type, indication, approach, stage, and region.

The precision cardiovascular therapeutics industry is segmented by therapy type, indication, approach, stage, and region. Therapy type coverage includes gene therapy and RNA therapeutics followed by targeted small molecules. Biologics and precision biomarkers complete therapy coverage. Indication coverage addresses atherosclerotic cardiovascular disease and heart failure followed by cardiomyopathies. Familial hypercholesterolemia and arrhythmias complete indication coverage. Approach coverage includes genomics-guided and proteomics-based treatment followed by multi-omics and AI-driven personalization. Stage coverage spans marketed therapies and Phase III programs followed by Phase II and preclinical assets. Regional coverage includes North America and Europe together with East Asia. Latin America, South Asia and Pacific, and Middle East and Africa complete geographic assessment.

How does Gene Therapy shape therapy type selection?

Laffin and colleagues reported in November 2025 outcomes from 15 participants treated with CTX310 during a Phase I CRISPR and Cas gene study targeting ANGPTL3. Dose-linked reductions in ANGPTL3 and lipid measures established early biological activity among adults carrying refractory dyslipidemia, providing an initial basis for cardiovascular gene-editing assessment. Permanent editing narrows patient eligibility, since irreversible molecular change demands precise confirmation of the pathogenic pathway and careful exclusion of unsuitable candidates. Extended observation and structured registries record delayed safety events and treatment durability, enabling commercial reviewers to judge performance beyond the initial dose period.

• By therapy type, gene therapy is estimated to represent 41.0% share in 2026 since it reflects commercial interest in durable correction of inherited cardiovascular pathways. Hospital committees examine genomic confirmation and long-term surveillance as joint approval conditions, determining whether an irreversible intervention suits the diagnosed patient.
• RNA therapeutics preserve the option to alter dosing as clinical evidence develops, creating a different risk profile from permanent editing. Targeted small molecules and biologics address defined proteins without changing genomic sequence, offering physicians alternatives for patients lacking gene-therapy eligibility.

How does Atherosclerotic Cardiovascular Disease shape indication demand?

Atherosclerotic cardiovascular disease provides measurable lipid targets and established event endpoints, creating a practical basis for precision treatment assessment across preventive cardiology services. Bohula and colleagues reported in November 2025 a 25% reduction in first three-point major cardiovascular events with evolocumab among patients lacking prior myocardial infarction or stroke. Preventive evidence connects PCSK9-directed LDL-C reduction with fewer first cardiovascular events among patients selected by baseline risk and persistent lipid exposure. Commercial adoption rests on identifying residual risk and maintaining adherence across the intended care period.

• In 2026, atherosclerotic cardiovascular disease is anticipated to secure 35.0% share owing to large eligible populations and established event tracking. Preventive cardiology teams compare baseline risk against likely event reduction, establishing whether intensive treatment offers sufficient clinical value for each patient group.
• Heart failure and dilated cardiomyopathy programs address disease mechanisms differing from lipid-driven atherosclerosis, requiring separate diagnostic pathways and outcome measures. Familial hypercholesterolemia treatment and arrhythmia services add family screening or rhythm assessment, enabling clinicians to assign therapy from disease-specific evidence.

How does Genomics-guided care shape approach selection?

Genomics-guided care connects pathogenic variants with treatment choices across inherited cardiomyopathy and lipid disorders, giving specialists a disease-specific basis for therapeutic selection. Polygenic scores extend assessment into common cardiovascular disease, demanding ancestry-aware interpretation and explicit action thresholds prior to results entering clinical decision-making. Pharmacogenomic findings refine dose selection only if laboratory reports translate molecular results into a named clinical action understood by cardiologists and patients. National Institutes of Health reported in February 2024 more than 275 million previously unreported variants, expanding discovery resources for populations underrepresented in earlier genomic datasets.

• Genomics-guided is forecast to garner 44.0% share in 2026, guided by direct application of variant evidence during cardiovascular treatment selection within specialist care. Qualified counseling converts each molecular finding into a defined patient action used by cardiology teams, preventing laboratory results from remaining disconnected from clinical care.
• Proteomics measures pathway activity nearer to active disease physiology, adding clinical context beyond inherited sequence variation during cardiovascular assessment. Multi-omics and AI-driven personalization use bioinformatics to compare molecular layers under validated models, helping specialists distinguish meaningful signals during patient selection.

How does Marketed status shape stage leadership?

Marketed therapies provide regulatory clarity and documented prescribing instructions, allowing diagnosed cardiovascular populations to enter established treatment pathways under defined clinical oversight. Reimbursement review draws on approved indications and registration evidence, creating a recognized basis for coverage decisions across specialist and payer organizations. United States Food and Drug Administration records issued in November 2024 show ATTRUBY approval relied on 611 patients with transthyretin cardiomyopathy. Approved status moves molecular diagnosis into routine prescribing; earlier-stage assets retain greater efficacy and safety uncertainty during commercial evaluation.

• Based on stage, marketed therapies are projected to hold 42.0% share in 2026 as they are aided by prescribing familiarity and established safety monitoring across diagnosed patient groups. Specialist recognition reduces delay between molecular diagnosis and treatment initiation, improving access among eligible patients served by dedicated cardiomyopathy programs.
• Phase III programs require outcome confirmation among larger patient groups, and Phase II studies refine dose and biological response under narrower protocols. Preclinical programs examine target validity and delivery prior to human exposure, leaving developers with a longer path toward regulatory and commercial review.

What are drivers, restraints, and opportunities in precision cardiovascular therapeutics market?

Molecularly selected treatments advance therapy evaluation across cardiovascular services. Uneven diagnostic access and incomplete subgroup evidence may delay routine adoption.

• Driver: Cardiovascular teams require treatments addressing defined biological pathways with measurable outcome improvement. Molecular eligibility creates accountable prescribing across specialist services.
• Restraint: Uneven demographic representation limits confidence across populations carrying different genetic profiles. Fragmented testing access may extend diagnosis and delay treatment initiation.
• Opportunity: Diverse genomic cohorts may improve risk assessment across underrepresented ancestry groups. Representative evidence strengthens clinical confidence across preventive and therapeutic programs.

Specialist programs are expected to use such findings during transthyretin cardiomyopathy treatment review. Alnylam Pharmaceuticals reported in June 2024 a 28% reduction in all-cause mortality and recurrent cardiovascular events for the full vutrisiran population. Outcome evidence connects RNA silencing with clinical cardiovascular benefit.

Mutema and colleagues reviewed 838 publications in March 2025 and found inconsistent reporting of sex and race across cardiovascular studies. Incomplete demographic reporting restricts subgroup interpretation for molecularly selected treatments. Developers may face added evidence requirements during regulatory and reimbursement assessment.

National Human Genome Research Institute information published in February 2024 described a subsequent polygenic-risk study phase targeting 25,000 participants from diverse populations. Ancestry-inclusive cohorts may strengthen coronary risk classification across preventive cardiology services. More representative models are anticipated to improve diagnostic confidence across underserved populations.

How are country CAGRs aligned in precision cardiovascular therapeutics market?

Country or Market	CAGR
USA	12.0%
Japan	11.8%
UK	10.9%
South Korea	8.4%
Germany	8.1%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in precision cardiovascular therapeutics market?

The country comparison shows a gradual step-down in growth across the markets covered. The United States and Japan occupy the upper end of the range, followed by the United Kingdom in the middle position. South Korea and Germany form a closely grouped lower tier. Germany records the lowest CAGR among the profiled countries. The 3.9 percentage-point spread indicates that these markets share a positive outlook, although their relative positions reflect different levels of market momentum.

• The United States and Japan lead the comparison and establish the principal development cluster among the countries shown.
• The United Kingdom follows the leading countries and maintains a limited gap from the upper group.
• South Korea and Germany form the next growth band, with only a narrow difference between their forecast rates.
• Germany records the slowest growth among the listed countries, yet its forecast remains positive within the wider market context.
• The pattern resembles a gradual downward slope rather than a sharp separation between faster-growing and slower-growing countries.

Countries with broadly similar CAGRs can present different entry conditions due to genomic infrastructure and cardiovascular treatment readiness. The full report provides country-level analysis across North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

Country-wise Analysis

• Demand in the United States is estimated to rise at 12.0% CAGR between 2026 and 2036, influenced by extensive genomic research capacity and early access to targeted cardiovascular medicines. National cohorts create practical resources for variant interpretation and subgroup analysis among patients carrying defined cardiovascular risks. All of Us reported in February 2025 research data from more than 633,000 participants, enlarging the evidence base available for precision treatment development.
• RIKEN reported in May 2024 whole-genome analysis using 3,256 Biobank Japan samples, improving population-specific interpretation of genetic variation among Japanese research participants. Academic medical centers provide controlled settings for molecular diagnosis and longitudinal observation across inherited cardiovascular disorders. Sector in Japan is predicted to expand at 11.8% CAGR during the forecast period, driven by concentrated expertise and measured adoption across hospital programs.
• National genomic services connect laboratory testing with longitudinal clinical records across England, creating a consistent pathway for cardiovascular research and clinical evidence review. Industry in the United Kingdom is projected to scale at 10.9% CAGR from 2026 to 2036, backed by standardized testing processes and public assessment of clinical utility. NHS England reported in December 2024 delivery of 809,888 genomic reports during 2023/24, demonstrating infrastructure capable of handling substantial testing activity.
• Macrogen reported in December 2024 responsibility for producing 145,952 whole-genome datasets under Korea's national bio-data project, documenting extensive sequencing activity planned for local research. The market in South Korea is anticipated to record 8.4% CAGR during the study period, aided by coordinated genomic investment and domestic analysis capability. Commercial progress requires cardiovascular applications capable of converting national data resources into treatment decisions for diagnosed patient groups.
• Regulated genomic integration creates a disciplined route for adding molecular evidence to cardiovascular care across accredited German clinical and laboratory settings. Federal Ministry of Health information updated in March 2026 described an interdisciplinary 14-member consortium within genomeDE, reflecting formal patient and clinical participation. Sales in Germany are anticipated to rise at 8.1% CAGR during the assessment period, helped by structured evidence assessment and measured clinical integration.

Who are notable companies in precision cardiovascular therapeutics market?

Novartis supplies lipid-lowering therapies aligned with molecular treatment pathways. Alnylam Pharmaceuticals develops RNA interference medicines for inherited cardiovascular disorders. Arrowhead Pharmaceuticals adds RNA-based treatment across genetically defined lipid conditions. BridgeBio Pharma provides disease-modifying treatment for transthyretin cardiomyopathy.

Competition in precision cardiovascular therapeutics is anticipated to center on target quality and cardiovascular outcome evidence. Clinical teams are likely to compare companies using diagnostic alignment and long-term safety records prior to treatment adoption. Novartis is expected to receive attention from established lipid-management access. Alnylam Pharmaceuticals is projected to advance RNA-therapy use using cardiomyopathy evidence. Arrowhead Pharmaceuticals is estimated to expand commercial RNA medicine across inherited lipid disorders. BridgeBio Pharma is anticipated to compete in transthyretin cardiomyopathy using approved disease-modifying treatment.

• Novartis and Amgen are expected to gain review attention from established cardiovascular treatment portfolios. Clinical teams are likely to assess outcome evidence and dosing schedules across lipid-management pathways.
• Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals are anticipated to compete using RNA-based therapeutic platforms. Cardiovascular programs are projected to compare target specificity and dosing durability across inherited disorders.
• BridgeBio Pharma and AstraZeneca are forecast to advance disease-specific treatment development across cardiomyopathy programs. Regulatory progress and patient-identification pathways are expected to influence specialist review.
• CRISPR Therapeutics and Kardigan are likely to receive development interest across gene-editing and precision cardiovascular programs. Trial progression is anticipated to influence future assessment among selected patient populations.

Competitive Benchmarking: Precision Cardiovascular Therapeutics Market

Company	Portfolio Depth	Clinical Match	Service Support	Service Reach
Novartis AG	High	High	High	Global markets
Alnylam Pharmaceuticals, Inc.	High	High	High	United States and selected global markets
Arrowhead Pharmaceuticals, Inc.	Medium	High	Medium	United States and selected international markets
BridgeBio Pharma, Inc.	Medium	High	Medium	United States and selected global markets

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Precision Cardiovascular Therapeutics Market

• In March 2025, Alnylam Pharmaceuticals announced United States approval of AMVUTTRA for adults with transthyretin cardiomyopathy. Approved labeling includes reduced cardiovascular mortality and urgent heart-failure visits. Commercial availability extended RNA interference into disease-modifying cardiovascular treatment.
• In November 2025, Arrowhead Pharmaceuticals announced United States approval of REDEMPLO for adults with familial chylomicronemia syndrome. Approval established an siRNA treatment option for a genetically defined lipid disorder. Commercial entry moved Arrowhead Pharmaceuticals from clinical development into precision cardiovascular medicine.
• In July 2026, Ionis Pharmaceuticals and AstraZeneca reported CARDIO-TTRansform missed its primary composite endpoint in transthyretin cardiomyopathy. Results narrowed immediate eplontersen positioning in cardiovascular amyloidosis. Clinical assessment shifted toward subgroup findings and biomarker evidence.

Key Players in Precision Cardiovascular Therapeutics Market

Established cardiovascular medicine companies

• Novartis AG
• Amgen Inc.
• AstraZeneca PLC

RNA therapeutics companies

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.

Cardiomyopathy and gene-editing companies

• BridgeBio Pharma, Inc.
• CRISPR Therapeutics AG
• Kardigan, Inc.

Precision Cardiovascular Therapeutics Market Report Scope

Coverage field	Report scope
Market breakdown	Precision Cardiovascular Therapeutics Market breakdown by therapy type, indication, approach, stage, and region
Market Definition	Precision cardiovascular therapeutics include treatments and selection tools using genomic or molecular evidence to guide cardiovascular care.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa
Countries Covered	USA, Japan, UK, South Korea, and Germany
Key Companies Profiled	Novartis AG, Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, Ionis Pharmaceuticals, Inc., BridgeBio Pharma, Inc., CRISPR Therapeutics AG, and Kardigan, Inc.
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using segment share and country CAGR with patient eligibility. Treatment adoption and regulatory status complete assessment.

Source: Future Market Insights analysis, 2026.

Precision Cardiovascular Therapeutics Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Future Market Insights analysis, 2026.

Precision Cardiovascular Therapeutics Market by Segments

Precision Cardiovascular Therapeutics Market segmented by Therapy Type:

• Gene Therapy
• RNA Therapeutics
• Targeted Small Molecules
• Biologics
• Precision Biomarkers

Precision Cardiovascular Therapeutics Market segmented by Indication:

• Atherosclerotic Cardiovascular Disease
• Heart Failure
• Cardiomyopathies
• Familial Hypercholesterolemia
• Arrhythmias

Precision Cardiovascular Therapeutics Market segmented by Approach:

• Genomics-guided
• Proteomics-based
• Multi-omics
• AI-driven Personalization

Precision Cardiovascular Therapeutics Market segmented by Stage:

• Marketed
• Phase III
• Phase II
• Preclinical

Precision Cardiovascular Therapeutics Market segmented by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Novartis. (2025, July 31). Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use.
• Our Future Health. (2025, September 18). New volunteer data added to our researcher database.
• Laffin, L. J., Nicholls, S. J., Scott, R. S., Clifton, P. M., Baker, J., Sarraju, A., Singh, S., Wang, Q., Wolski, K., Xu, H., Nielsen, J., Patel, N., Duran, J. M., & Nissen, S. E. (2025, November 8). Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3. New England Journal of Medicine, 393, 2119-2130.
• Bohula, E. A., Marston, N. A., Bhatia, A. K., De Ferrari, G. M., Leiter, L. A., Nicolau, J. C., Park, J. G., Kuder, J. F., Murphy, S. A., Walsh, E., Wang, H., Blaha, V., Budaj, A., Cornel, J. H., Goudev, A., Kiss, R. G., Lorenzatti, A. J., Parkhomenko, A., Cyrille, M., ... Sabatine, M. S. (2025, November 8). Evolocumab in patients without a previous myocardial infarction or stroke. New England Journal of Medicine, 394, 117-127.
• National Institutes of Health. (2024, February 19). 275 million new genetic variants identified in NIH precision medicine data.
• USA Food and Drug Administration. (2024, November 22). Drug Trials Snapshot: ATTRUBY.
• Alnylam Pharmaceuticals, Inc. (2024, June 24). Alnylam reports positive topline results from HELIOS-B Phase 3 study of vutrisiran, achieving statistical significance on primary and all secondary endpoints in both overall and monotherapy populations.
• Mutema, M., Roswell, R., Shenoy, V., Li, A., Samuels, S., Ishola, F. O., Arman, M. E., & Walsh, M. N. (2025, March 28). Analysis of clinical trial diversity in cardiology journals. JACC, 85(12 Supplement), 597.
• National Human Genome Research Institute. (2024, February 19). Researchers optimize genetic tests for diverse populations to tackle health disparities.
• National Institutes of Health, All of Us Research Program. (2025, February 24). All of Us adds data from 50% more participants in largest data expansion to date.
• RIKEN. (2024, May 9). Decoding the three ancestral components of the Japanese people.
• NHS England. (2024, December 3). Annex: operational performance update.
• Macrogen. (2024, December 9). Macrogen selected as final contractor for Korea's largest bio big data project.
• Federal Ministry of Health. (2026, March 2). genomeDE - National Strategy for Genomic Medicine.
• Alnylam Pharmaceuticals, Inc. (2025, March 20). Alnylam announces FDA approval of AMVUTTRA® (vutrisiran), the first RNAi therapeutic to reduce cardiovascular death, hospitalizations and urgent heart failure visits in adults with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
• Arrowhead Pharmaceuticals, Inc. (2025, November 18). Arrowhead Pharmaceuticals announces FDA approval of REDEMPLO® (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
• Ionis Pharmaceuticals, Inc. (2026, July 9). Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy.

This bibliography is provided for reader reference and is not exhaustive. Full report coverage includes complete source records and detailed verification.

This Report Answers

• What segments influence demand across therapy type, indication, approach, and stage?
• How do cardiology teams evaluate precision cardiovascular therapeutics prior to routine clinical use?
• How do country CAGRs differ across profiled markets with distinct genomic capacity and specialist access?
• What companies compete using therapeutic depth and cardiovascular evidence?
• How are forecasts validated using hybrid bottom-up and top-down analysis?
• What evidence do hospital committees examine prior to treatment adoption?
• How do molecular eligibility and diagnostic access influence therapy selection?
• What limits return on investment across precision cardiovascular treatment programs?
• How do specialist education and monitoring requirements influence clinical approval?
• What company capabilities improve long-term confidence and continuing treatment use?